PRESSEMITTEILUNGEN

At Medica 2011, FotoFinder presents the future of early skin cancer detection. In the center of attention is the fast diagnostic exchange between doctors using mobile communication technology. With handyscope for iPhone and the corresponding App, FotoFinder has linked dermoscopy with smartphone technology. Now, the new online-platform Hub allows doctors to upload handyscope pictures to [...]

Continue reading

Bild, Cancer Center, Cancer Detection, Center Of Attention, Doctors, Fotofinder, Hub, Iphone, Mit, Mobile Communication Technology, Presents, Private Webspace, Skin Cancer, Skin Cancer Diagnosis, Technology New, Web Database

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Molecular diagnostics Berlin, Germany, and Laval, QC, Canada, December 6, 2010 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX), a cancer molecular diagnostics company and Warnex Medical Laboratories, a division of Warnex Inc. (TSX: [...]

Continue reading

Apparent Disease, Berlin Germany, Blood Testing, Busgang, Canadian Healthcare, Cancer Detection, Chief Executive Officer, Colorectal Cancer Patients, Colorectal Cancer Test, Dna Methylation, Epigenomics Ag, Laval Qc, Medical Laboratories, Molecular Diagnostics, Prime Standard, Qc Canada, Real Time Pcr Technology, Time Pcr, Warnex Inc, Wnx

Independent validation of laboratory test used in PRESEPT Study shows that the test finds 86% of the cancers ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Molecular diagnostics Subtitle: Independent validation of laboratory test used in PRESEPT Study shows that the test finds [...]

Continue reading

Barcelona Spain, Benchmark Study, Biomarker, Cancer Cases, Cancer Detection, Cancer Diagnostics, Colonoscopy, Colorectal, Colorectal Cancer Screening, Company Announced That, Discoverer, Epigenomics, European Gastroenterology, Independent Validation, Laboratory Test, Medical Affairs, Molecular Diagnostics, Poster Presentation, Prospective Evaluation, Senior Vice President

Differences in analytical instrument read-out requires verification and potential retesting of samples measured in laboratory with deviating results Top-line data expected still in Q1 2010 No impact on commercial strategy expected ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Research & Development/Molecular Diagnostics/Products Subtitle: [...]

Continue reading

Adhoc, Ag Reports, Analytical Instrument, Berlin Germany, Biomarker, Blood Plasma, Cancer Detection, Cancer Patients, Case Control Studies, Commercial Strategy, Control Subjects, Epigenomics, Molecular Diagnostics, Plasma Samples, Preliminary Results, Prime Standard, Seattle Wa, Study Steering Committee, Study Subjects, Testing Laboratories

——————————————————————————– ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Molecular diagnostics 15.01.2010 Berlin, January 15, 2010 – Epigenomics AG (ISIN: DE000A0BVT96), a cancer molecular diagnostics company, informs on preliminary data [...]

Continue reading

American Cancer Society, Biomarker, Blood Plasma, Cancer Detection, Cancer Screening Study, Chapel Hill Nc, Church Ph, D University, Epigenomics Ag, German Securities Trading Act, Minneapolis Mn, Molecular Diagnostics, Plasma Samples, Principle Investigator, Prospective Multi Center, Ransohoff, Securities Trading Act, Study Objective, Study Steering Committee, University Of Minnesota Minneapolis

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Licensing Agreements/Molecular Diagnostics Press release, Berlin, Germany, and Seattle, WA, USA, November 2, 2009 (euro adhoc) – The cancer molecular diagnostics company Epigenomics AG (Frankfurt Prime Standard: ECX) today announced that Quest Diagnostics Incorporated, Madison, [...]

Continue reading

Berlin Germany, Cancer Detection, Chief Executive Officer, Clinical Validation, Colorectal, Colorectal Cancer, D Vice, Development Partner, Diagnostic Testing, Dna Methylation, Licensing Agreements, Madison Nj, Milestone Payment, Molecular Diagnostics, Prime Standard, Quest Diagnostics, Quest Diagnostics Incorporated, Seattle Wa Usa, Successful Development, Wohlgemuth

The Swiss private diagnostic laboratory will launch mSEPT9 blood testing service for colorectal cancer early detection on July 1, 2009 ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– new product/Molecular Diagnostics Press release, Berlin, Germany, and Seattle, WA, USA, June 23, 2009 – (euro [...]

Continue reading

Berlin Germany, Biomarker, Blood Sampling, Blood Testing, Cancer Detection, Chairman Board, Colorectal Cancer Screening, Diagnostic Laboratories, Diagnostic Laboratory, Dna Methylation, Eans, Epigenomics Ag, Gastroenterologists, Laboratory Diagnostics, Laboratory Network, Molecular Diagnostics, Prime Standard, Professional Laboratory, Seattle Wa Usa, True Innovation

mSEPT9 biomarker facilitates innovative blood test for colorectal cancer mSEPT9 data published in Clinical Chemistry PRESEPT Study for colorectal cancer screening with mSEPT9 well on track ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– new product/research/Molecular diagnostics Press release, Berlin, Germany, and Seattle, WA, [...]

Continue reading

Biomarker, Cancer Detection, Cancer Screening, Case Control Studies, Clinical Chemistry, Clinical Validation, Colorectal Cancer, Ddw, Digestive Disease Week, Dna Methylation, Dr Catherine, Eans, Epigenomics Ag, Gastroenterologists, Molecular Biology, Molecular Diagnostics, New Product Research, Poster Presentation, Prestigious Conference, Seattle Wa Usa

Biomarker mPITX2 for prostate cancer prognostic application successfully validated First clinical laboratory in Germany to start offering mPITX2 testing service ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– new product/research/Molecular diagnostics Press release, Berlin, Germany and Seattle, WA, USA, May 29, 2009 (euro adhoc) [...]

Continue reading

Berlin Germany, Cancer Detection, Disease Recurrence, Dna Methylation, Eans, Epigenomics Ag, Molecular Diagnostics, New Product Research, Orlando Florida Usa, Poster Presentation, Prime Standard, Prostate Cancer, Prostate Cancer Patients, Prostate Cancer Prognosis, Prostate Cancer Risk, Prostatectomy, Rational Design, Risk Groups, Seattle Wa Usa, Validation Study

Patents cover biomarker mPITX2 for prostate and breast cancer indications ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– new product/molecular diagnostics Berlin, Germany, and Seattle, WA, USA, May 13, 2009 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX), a molecular diagnostics company focusing [...]

Continue reading

American Urological Association, Breast Cancer, Breast Cancer Patients, Cancer Detection, Cancer Indications, Disease Recurrence, Dna Methylation, Duke University, Epigenomics Ag, European Patent Office, Patent And Trademark Office, Patent Application, Patent Applications, Prostate Cancer, Prostate Cancer Prognosis, Seattle Wa Usa, United States Patent, United States Patent And Trademark Office, Urology Community, Validation Study